<DOC>
	<DOCNO>NCT00382395</DOCNO>
	<brief_summary>Study Objective : To establish substantial equivalence SOLX Gold Shunt commercially available aqueous shunt , specifically Ahmed™ Glaucoma Valve Model FP7 , ability reduce intraocular pressure ( IOP ) associate glaucoma eye medical conventional surgical treatment fail .</brief_summary>
	<brief_title>SOLX Gold Shunt Versus Control Implant : Randomized Trial Refractory Glaucoma</brief_title>
	<detailed_description>This protocol randomize , control , multi-center , outpatient study compare IOP lower ability safety profile SOLX Gold Shunt select , commercially available aqueous shunt product ( i.e. , Control shunt Model FP7 Ahmed™ Glaucoma Valve Flexible Plate™ ) period one year . Extended follow schedule period exceed two year , necessary regulatory purpose . Follow-up beyond one year expect unless patient SOLX Gold Shunt implant earlier phase study outside US clearly show significant adverse effect associate long-term use device follow-up period exceed one year , information deem adequate reduce require follow-up period protocol shorter period , 6 month last-to-enter patient time file 510 ( k ) marketing clearance review FDA .</detailed_description>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<criteria>Primary openangle , pseudoexfoliative , pigmentary glaucoma Age 21 refractory glaucoma , IOP &gt; 21 mmHg medication fail prior incisional glaucoma surgery detectable visual field defect ( negative MD score ) write consent available 24 month followup either eye VA bad count finger recent angle closure glaucoma episode uveitic glaucoma , iridocorneal endothelial ( ICE ) syndrome , traumatic glaucoma , neovascular glaucoma significant ocular disease , except cataract active ocular infection expect ocular surgery next 12 month suitable quadrant implant systemic corticosteroid therapy &gt; 5 mg/day prednisone intolerance gonioscopy eye exams mental impairment interfere consent compliance pregnancy know sensitivity anticipate medication use surgery significant comorbid disease concurrent enrollment another drug device study</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Glaucoma shunt</keyword>
	<keyword>Ocular implant</keyword>
	<keyword>Gold</keyword>
	<keyword>trabeculectomy</keyword>
</DOC>